|
|
Volumn 49, Issue 5, 2013, Pages 341-345
|
|
A report from the 65th annual meeting of the American Academy of Neurology (March 16-23, 2013, San Diego, California, USA)
|
|
Author keywords
Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Spinal muscular atrophy
|
|
Indexed keywords
AC 838;
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
ANALGESIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
ARBACLOFEN PLACARBIL;
BAF 312;
FINGOLIMOD;
IMMUNOGLOBULIN;
ISIS SMN;
MU OPIATE RECEPTOR AGONIST;
NUCLEAR RECEPTOR RELATED FACTOR 1;
ORM 12741;
PLACEBO;
SIPONIMOD;
SURVIVAL MOTOR NEURON PROTEIN 2;
TRV 130;
UNCLASSIFIED DRUG;
VESICULAR MONOAMINE TRANSPORTER 2;
ALZHEIMER DISEASE;
AMYOTROPHIC LATERAL SCLEROSIS;
BACKACHE;
BRADYCARDIA;
BRAIN ATROPHY;
BRONCHITIS;
CELL SURVIVAL;
CLINICAL DEMENTIA RATING;
COGNITION;
CONFERENCE PAPER;
CONSTIPATION;
CONTINUOUS INFUSION;
DIARRHEA;
DIZZINESS;
DRUG DOSE REDUCTION;
DRUG DOSE TITRATION;
DRUG HALF LIFE;
DRUG POTENCY;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
EPISODIC MEMORY;
FATIGUE;
FEVER;
FIRST IN HUMAN STUDY;
FOLLOW UP;
FORCED VITAL CAPACITY;
HEADACHE;
HEART RATE;
HERPES ZOSTER;
HUMAN;
LOCOMOTION;
LONG TERM CARE;
LYMPHOCYTE COUNT;
MAXIMUM TOLERATED DOSE;
MEAN ARTERIAL PRESSURE;
MILD COGNITIVE IMPAIRMENT;
MINI MENTAL STATE EXAMINATION;
MULTIPLE SCLEROSIS;
MUSCLE STRENGTH;
NAUSEA;
NAUSEA AND VOMITING;
NERVE FIBER GROWTH;
NEUROLOGIST;
NEUROLOGY;
NEUROSCIENCE;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PARKINSON DISEASE;
PHARYNGITIS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROTEIN TARGETING;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RHINOPHARYNGITIS;
SIDE EFFECT;
SINGLE DRUG DOSE;
SINUSITIS;
SOMNOLENCE;
SPASTICITY;
SPINAL MUSCULAR ATROPHY;
STREPTOCOCCAL PHARYNGITIS;
SUSTAINED RELEASE PREPARATION;
UNITED STATES;
UPPER RESPIRATORY TRACT INFECTION;
URINARY TRACT INFECTION;
VOMITING;
WORKING MEMORY;
ANIMAL;
CLINICAL TRIAL (TOPIC);
DRUG DESIGN;
MOLECULARLY TARGETED THERAPY;
NEUROLOGIC DISEASE;
PATHOPHYSIOLOGY;
ALZHEIMER'S DISEASE;
AMYOTROPHIC LATERAL SCLEROSIS;
MULTIPLE SCLEROSIS;
SPINAL MUSCULAR ATROPHY;
ANIMALS;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
HUMANS;
MOLECULAR TARGETED THERAPY;
NERVOUS SYSTEM DISEASES;
MLCS;
MLOWN;
|
|
EID: 84878706639
PISSN: 16993993
EISSN: 16994019
Source Type: Journal
DOI: 10.1358/dot.2013.49.5.1976050 Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (0)
|
